had similar hemodynamic and clinical characteristics and hormonal profile at baseline evaluation. In the untreated patients, volume expansion did not increase left ventricular end-diastolic volume measured by echocardiography and was associated with a reduction in ejection fraction (p<0.05) and with a paradoxical increase in forearm vascular resistance (p<0.05) estimated by plethysmography. In addition, plasma atrial natriuretic factor did not change, and plasma norepinephrine was increased by saline loading. In contrast, in the patients treated with quinapril, volume expansion induced an increase of both left ventricular volumes (p<0.001) without changing ejection fraction and reduced forearm vascular resistance (p<0.05). In addition, in this group, plasma atrial natriuretic factor levels increased (p<0.05) and plasma norepinephrine did not change during volume overload. During nitroglycerin infusion, volume expansion was associated with peripheral vasodilatation, increases of left ventricular volumes, and no change in ejection fraction. In this group, however, plasma atrial natriuretic factor levels did not change in response to volume overload.
Conclusions. We conclude that pretreatment with the ACE inhibitor quinapril significantly improves compromised responses to acute isotonic volume overload in patients with dilated cardiomyopathy and mild heart failure. The favorable influence of ACE inhibition on cardiovascular and hormonal responses to volume expansion seems to be related to the cardiac unloading produced by this treatment. (Circulation 1992;86:1800-1809) KEY WORDs * atrial natriuretic factor * nitroglycerin * renin * angiotensin * quinapril C atrial peptides A ngiotensin converting enzyme (ACE) inhibitors are widely used in the treatment of patients with heart failure.'-3 Long-term therapy with ACE inhibitors, in fact, is associated with favorable effects on hemodynamics4-6 and improvement of exercise capacity in patients with congestive heart failure.7-9 Furthermore, ACE inhibitors prolong survival in patients with heart failure in New York Heart Association (NYHA) functional class IVIO as well as in patients with mild left ventricular dysfunction, as recently shown in the SOLVD study." Although the beneficial influence of ACE inhibitors on systemic hemodynamics at rest and in response to physical exercise is well documented,49-12 very little is known about the effects of these compounds on cardiovascular adaptation to volume overload, which represents a hallmark of heart failure. In this latter regard, we have recently demonstrated that remarkable abnormalities of the preload reserve mechanisms are unmasked by acute isotonic volume expansion in patients with idiopathic or ischemic dilated cardiomyopathy and asymptomatic to mildly symptomatic heart failure (NYHA classes I-JI).13 These abnormal responses to volume loading, which include inadequate hemody- CAD  ICM  CAD  CAD  ICM  ICM  ICM  ICM  ICM  CAD  CAD  CAD  CAD   NYHA  functional class  I  II  I  II  I  II  II  II  I  I  II  I  I  I  I  I  I  I  II  II  I  II  I  II  II  I  I  II  II  I  II  II   LVEDD  (mm)  63  62  57  60  61  67  61  65  68  62  69  67  58  55  70  55  58 N/A NYHA, New York Heart Association; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction measured in the supine position by radionuclide technique; EDT, exercise duration time; peak Vo2, total body oxygen consumption at peak exercise; CAD, coronary artery disease; ICM, idiopathic dilated cardiomyopathy; N/A, not available. *Subjects studied with quinapril; tsubjects studied with nitroglycerin. namic adjustments, impaired atrial natriuretic factor (ANF) release, and blunted renin-aldosterone suppression and natriuretic response, may be more pronounced or even precede a significant reduction of the exercise capacity.'3"4
The aim of this study was to establish whether ACE inhibition modifies the cardiorenal and hormonal responses to volume load in patients with dilated cardiomyopathy and mild heart failure. It 
Study Subjects and Patients
The initial study population included 35 patients with dilated cardiomyopathy and chronic, stable, mild heart failure. The patients were recruited by selection of consecutive patients in the outpatient clinic for cardiovascular diseases of our institution. The experimental protocol was approved by the Ethical Committee of our institution, and each subject gave written, informed consent before entering the study. The study was completed in 32 subjects (27 men and five women) ranging in age from 32 to 60 years (mean+SEM, 49±1 years).
The individual characteristics of these subjects are presented in Table 1 . The cause of heart failure was idiopathic dilated cardiomyopathy in 17 and coronary artery disease in 15 subjects. Patients were considered to have an idiopathic dilated cardiomyopathy when no obvious underlying cause of heart failure could be discovered during routine evaluation. The 41 .4+1%) on at least one measurement within 3 months before the study. Nineteen of the patients had received treatment with digitalis, nitrates, and/or diuretics before the study. The distribution of these patients among the study groups was uniform.
Experimental Protocol
All drug therapy was discontinued at least 3 days before the study. Alcohol, caffeine, cigarettes, and physical exercise were all prohibited within 24 hours of the study. After admission to the clinic ward, all subjects were maintained on a daily diet containing 100 meq of sodium, 50 meq of potassium, and 1,500 ml of water. Daily 24-hour urine collections were analyzed for sodium, potassium, and creatinine excretion. When a steady state of urinary sodium excretion was achieved, each subject was assigned to a study group according to a computer-based scheme of randomization.
The study was begun at 7:30 AM with the subject in a comfortable sitting position after voiding. The temperature (22°C) and the lights of the study room were maintained constant. The patient was asked to drink 500 ml of water to ensure sufficient urinary flow. Thirty minutes after insertion of two intravenous lines into superficial forearm veins, 20-minute baseline clearance periods were performed. Throughout the study, at the end of each period, the patients drank an amount of water equivalent to the sum of blood losses and urinary flow. As soon as balance was achieved (consistent urinary volumes in two consecutive clearance periods), average of the urinary, hormonal, and hemodynamic measurements obtained during the two baseline periods was used for the analysis. Subsequently, an intravenous isotonic saline load (0.9% NaCl, 0.25 ml * kg-1 min-m) was started and maintained at constant rate for 2 hours. Arterial blood pressure was measured at 10-minute intervals by standard sphygmomanometric technique, following the recommendations of the American Heart Association.21 Heart rate was continuously monitored by ECG lead II. Urinary samples for determination of volume, sodium, and potassium were obtained at the end of each clearance period. Venous blood samples for determination of hematocrit, plasma renin activity, aldosterone, norepinephrine, and immunoreactive ANF levels were obtained at 30-minute intervals.
Forearm blood flow and calculated vascular resistance were measured at 60-minute intervals by straingauge plethysmography. M-and B-mode echocardiograms were also recorded at 60-minute intervals for measurements of atrial and ventricular dimensions, calculation of left ventricular EF, and estimation of stroke volume and the derived parameters.
The patients studied without active treatment ("untreated," n = 14) received a tablet of placebo in the week preceding the study.
To evaluate the effects of the inhibition of the reninangiotensin system on hormonal and cardiorenal responses to volume loading, the saline load (at the rate indicated above) was performed after 7 days of treatment with quinapril (Malesci, Florence, Italy), an ACE inhibitor with a prolonged effect on plasma and tissue converting enzymes,22 at a dosage of 10 mg/day p.o. administered every night at 8 PM (n=11). This dose of quinapril has been shown to induce sustained inhibition of ACE (about 90% 12 hours after administration).22 '23 To further explore the mechanisms underlying the effects of ACE inhibition on the adaptations to acute volume expansion, in four of the patients from each group (untreated or treated with quinapril), right atrial pressure was monitored continuously during the study by means of a catheter introduced via a superficial forearm vein and connected to a polygraph by a pressure transducer.
Finally, to evaluate the influence of vasodilation, in seven of the patients from the enrolled population, the effects of saline load were evaluated during the steadystate phase of a constant intravenous infusion of nitroglycerin at a dosage of 0.1 gg kg 1 * min-. The saline load (same rate of infusion) was started when blood pressure and diuresis had achieved stability (usually within 60 minutes).
Laboratory Methods
Blood samples for plasma ANF and norepinephrine levels were collected on ice and spun immediately (within 10 minutes); blood samples for measurement of plasma renin activity and aldosterone concentrations were collected at room temperature. The plasma was then separated and frozen until the time of assay, which did not exceed 4 weeks.
Plasma renin activity was measured by enzymatic assay,24 in which plasmas were incubated at 37°C for 3 hours in the presence of endogenous angiotensinogen and ACE and angiotensinase inhibitors (phenylmethyltwo 30-minute baseline periods were observed and the sulfonil fluoride and EDTA). The pH was adjusted at 5.7 with maleic acid. The angiotensin I formed was quantified by radioimmunoassay, and results were expressed as the hourly rate of angiotensin I generation (ng * ml`* hr-t) (sensitivity, 10 pg/tube angiotensin I; intra-assay and interassay variability coefficients, 3.7% and 7.6%, respectively). Plasma immunoreactive ANF levels were determined by radioimmunoassay as previously described by our laboratory,25 with rabbit antiserum (RAS 8798, Peninsula Laboratories Europe), iodinated human ANF-(99-126) (2,000 Ci/mmol, Amersham Berks, UK), and a-human ANF-(99-126) (Bissendorf GmbH Peptide) as a standard. ANF was extracted from plasma with Sep-Pak C18 cartridges. The recoveries determined on each plasma sample by adding to it a minimal amount of radiolabeled ANF ranged from 75% to 90%. Intra-assay and interassay variation coefficients were 6.8% and 10.1%, respectively. The radioimmunoassay sensitivity was 3 pg/tube. Plasma aldosterone concentrations were estimated by a radioimmunoassay technique using a commercial kit (Sorin, Saluggia, Italy). Plasma norepinephrine assay was performed with reverse-phase high-performance liquid chromatography with electrochemical detection after extraction and concentration by adsorption onto activated alumina.26 Potassium and sodium levels in urine were measured by ion-selective electrodes (Beckman E2A Na/K system, Arlington Heights, Ill.).
Echocardiographic Measurements
Wide-angle, two-dimensional echoes were recorded with a phased-array sector scanner (77020 AC, HewlettPackard Co., Andover, Mass.).
All studies were videotaped on 3/4-in. videocassette recorders equipped with a back-spacer search module, which allows frame-by-frame bidirectional playback. The video frame rate of the system is approximately 60 frames per second.
All patients were studied in the sitting position with multiple views through the apical window. Two views were selected for measurements: apical four chamber and apical two chamber. The left ventricular long axis (L,,.) was measured at end diastole as the longest major axis in either of the two apical views. The Figure 1 . In the untreated subjects with dilated cardiomyopathy (Figure 1 , open figure) . Right atrial pressure, which was measured only in four patients from each group, increased in both the untreated patients (F=20.1, p<0.001) and in those receiving quinapril (F=17.4, p<0.05) during volume expansion (Figure 1) . Although the absolute values of right atrial pressure tended to be smaller in the quinapril-treated patients at any time point during the experiment, comparisons between the corresponding mean values did not achieve statistical significance. In addition, the slopes of the regression lines obtained by plotting atrial pressures versus time were not different (0.035±0.013 in the untreated group and 0.023±0.011 in the quinapril group).
The 1-week treatment with quinapril was associated with a significant reduction of systolic blood pressure and of total peripheral resistance, whereas diastolic blood pressure, heart rate, left ventricular volumes, and stroke volume did not change significantly (Table 3) .
When volume expansion was performed in the subjects with dilated cardiomyopathy pretreated with quinapril ( Figure 1, solid bars) , the hemodynamic responses were largely different from those observed in the untreated subjects. In particular, both end-diastolic (F=86.0,p<0.001) and end-systolic (F=41. 5 Table 3 , after 1 week of treatment with quinapril, a significant increase in plasma renin activity was observed. Plasma aldosterone and ANF levels tended to decrease, although statistical significance was not achieved. Finally, no significant changes in plasma norepinephrine concentrations or urinary sodium and potassium excretion were found.
In the untreated patients, volume expansion did not produce the expected increase of plasma ANF levels either at 60 or 120 minutes, even when this parameter was normalized by hematocrit ( Figure 2, open bars) . Urinary sodium excretion, however, was significantly increased after 120 minutes of saline load. Finally, plasma norepinephrine levels were increased at 120 minutes of volume expansion (p<0.05) (Figure 2) .
On the contrary, during ACE inhibition ( Figure 2 , solid bars), volume expansion was associated with a significant increase of ANF levels at both 60 and 120 minutes (F=6.88, p<0.05), which was significantly dif- Regression analysis showed a significant correlation between the changes in left ventricular end-diastolic volume and those of plasma ANF levels during volume expansion in the patients pretreated with quinapril (r=0.685, p<0.01) but not in the untreated patients (r=0.004, NS). Table 4 shows that volume expansion caused comparable effects on blood pressure, heart rate, hematocrit, plasma renin activity, and urinary potassium excretion. In contrast, two-way ANOVA showed more marked suppression of plasma aldosterone concentrations by volume load in the patients receiving the ACE inhibitor than in the untreated patients (F=4.94, p<0.05).
Responses to Volume Expansion During
Nitroglycerin Infusion
The effects of nitroglycerin infusion on baseline parameters and its influence on the responses to volume expansion are presented in Table 5 . During nitroglycerin infusion, systolic blood pressure and total peripheral resistance were significantly decreased, and heart rate increased from baseline. Both left ventricular volumes were reduced, and EF rose. Finally, plasma renin activity and norepinephrine levels increased (all p<0.05).
Volume expansion performed during the steady-state phase of nitroglycerin infusion was associated with further significant increases of left ventricular volumes and stroke volume and reduction of total peripheral resistance and heart rate. Under these conditions, plasma renin activity and aldosterone concentrations were reduced by volume expansion, whereas plasma ANF and norepinephrine levels failed to change. Discussion Volume overload is a fundamental hallmark of congestive heart failure, and most of the symptoms and physical signs that occur in this condition result in large measure from the inability to excrete sodium and water. Therefore, it is important to study the regulation of fluid and electrolyte balance as well as to characterize the influence of therapeutic interventions on the handling of sodium and water in heart failure. On the contrary, the pathophysiology of sodium and water retention remains one of the most poorly defined aspects of congestive heart failure, particularly with regard to the time of onset of this abnormality during the course of the disease. In 1965, Braunwald et a130 described in patients with valvular or congenital heart disease an inability to excrete sodium in response to a 1-week oral sodium tolerance test. Consistent findings were subsequently reported by other authors in patients with moderate to severe heart failure of different pathogenesis.31-33 More recently, we showed13 that in patients with dilated cardiomyopathy and mild heart failure, although basal hemodynamic, hormonal, and renal profiles are substantially within the normal range, as observed also by other authors,14,34 the responses to acute isotonic volume expansion are markedly impaired compared with those observed in normal subjects.
The results of the present study confirm and extend our previous observations demonstrating inadequate cardiac and hemodynamic adaptations and impaired ANF response13 to volume overload in patients with dilated cardiomyopathy and mild left ventricular dysfunction. These abnormal responses indicate that the inability to handle acute sodium chloride loading appears early in the evolution of heart failure, because it can be observed when no signs or symptoms of congestion are present, and more importantly, when baseline urinary sodium excretion rates are consistent with a relatively normal sodium excretory function.
The major finding of the present study, however, is that the impaired cardiovascular and hormonal response to volume expansion is reversible, because it is largely improved by a short-term pharmacological treatment. In fact, our study demonstrates that a 1-week treatment with the ACE inhibitor quinapril produces several significant, favorable changes in the cardiac, hormonal, and renal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure. This observation, which supports a beneficial influence of ACE inhibition on the adaptations to increased preload in heart failure, is generally consistent with previous findings reported by Cody et a133 showing improved cardiovascular and hormonal adjustments to upright tilt after 1 week of moderate increase of sodium intake in patients with congestive heart failure.
Detailed analysis of our results shows that significant increases of left ventricular end-diastolic volume and of echocardiographically assessed stroke volume were restored by ACE inhibition, which also prevented the reduction of EF observed in the untreated patients. In addition, after pretreatment with quinapril, the paradoxical rise of forearm vascular resistance and of calculated total peripheral resistance observed in the untreated patients during volume expansion shifted toward the physiological vasodilator response.
These hemodynamic effects of ACE inhibition were associated with notable changes of the ANF response to volume loading. After quinapril, in fact, a significant and consistent increase of plasma ANF levels was induced by volume expansion, as opposed to the lack of ANF response uniformly observed in the untreated subjects. Recovery of the physiological ANF response13,35 in these patients may reflect the improvement of ventricular function produced by quinapril. In fact, only in this latter group was the ANF response significantly correlated with the changes in left ventricular end-diastolic volume associated with volume expansion. Alternatively, the recovery of the ANF response may have resulted from the diminished baseline levels after treatment with the ACE inhibitor. Finally, the possibility that ACE inhibition may restore an impaired ANF secretory function in cardiomyopathic patients seems unlikely, because in the more severe and advanced stages of the disease, plasma ANF levels may increase further, suggesting preserved biosynthetic and secretory properties in this disease. 19, 36, 37 After treatment with quinapril, saline load was associated with a threefold higher urinary sodium excretion than in the untreated group. Among the different factors that might have contributed to this effect of quinapril, the improvement of cardiac output response to volume load may have augmented the natriuretic response through an increase of renal blood flow.38 In addition, the more profound suppression of aldosterone levels observed during saline load in the quinapril group may have contributed to the increase of the natriuretic response. This latter finding, associated with the observation that renin suppression was relatively preserved in our patients, indicates that the function of the macula densa mechanism is retained in heart failure, as previously reported by other authors.33 Finally, it is not clear whether the improvement of the ANF response to volume challenge contributed to the enhanced natriuretic response and aldosterone suppression39 observed in the quinapril group. However, the observations that in the untreated group, an increase of urinary sodium excretion occurred in the absence of any ANF change, or, more importantly, that the maximum absolute plasma ANF levels achieved during volume load were comparable in the untreated and in the quinapril-treated patients, seem to speak against such a possibility.
A paradoxical peripheral vasoconstriction was observed in the untreated subjects during volume overload. This phenomenon may be the consequence of inadequate ventricular distension and cardiac output in response to volume expansion. In fact, the impaired cardiac adaptation can be responsible for increased sympathetic activity,40 as suggested also by the elevation of plasma norepinephrine levels in our untreated pa- Figure  3 , which depicts the left ventricular end-diastolic volume/stroke volume relations in the untreated and quinapril-treated patients. Although this comparison should be interpreted with caution, because filling pressure was not measured, it seems evident that in the untreated patients, only a small increment of volume took place, and it was not associated with any change in stroke volume, suggesting an underutilization of the Frank-Starling mechanism. In contrast, after ACE inhibition, this relation improved, because both end-diastolic volume and stroke volume increased appropriately in response to volume load.
With regard to the studies with nitroglycerin, the well-known effects of nitrate-induced vasodilatation in producing a remarkable beneficial influence on cardiac hemodynamics in heart failure were also observed in our patients, in spite of the reflex rise of renin and norepinephrine. Thus, although both interventions (ACE inhibition and nitroglycerin) reduced cardiac load by lowering venous return and peripheral resis- tance, the favorable effects of ACE inhibition and nitroglycerin on the adaptation to volume loading may somehow recognize different mechanisms. In addition, the acute treatment with nitroglycerin was unable to restore the ANF response to volume expansion. This may imply that the adequate ANF response observed in the quinapril group either was a direct effect of the ACE inhibitor or reflected the fact that 1 week of treatment was required to achieve this adaptive response. Finally, the reduction of cardiac pressures during continuous nitrate infusion45 may have physically counteracted the atrial stretch produced by volume overload, thus antagonizing ANF release.4647
In conclusion, our study confirms the presence of early abnormalities of the dynamic cardiac and hormonal handling of volume load in patients with dilated cardiomyopathy and mild left ventricular dysfunction. These abnormalities are significantly improved by a short-term pretreatment with the ACE inhibitor quinapril.
The potential importance of the influence of ACE inhibitors on the adjustments to increased preload in their favorable therapeutic effect on the development of heart failure remains to be demonstrated. Our data, however, suggest that an early intervention with ACE inhibitors may improve the abnormal cardiorenal and hormonal adaptations produced by acute increases of blood volume, which may occur frequently during the daily activities of these patients. Such an effect could significantly contribute to the beneficial actions of ACE inhibitors in heart failure.
